NIH National Cancer Institute logo
NCI IMAT — Innovative Molecular Analysis Technologies

NCI IMAT R61 & R33

Supports translational cancer technology from concept proof to advanced development through NCI.

Between cyclesNIH National Cancer InstituteUnited States
View on funder site
About

The NCI Innovative Molecular Analysis Technologies (IMAT) program funds early-stage development of novel analytical technologies for cancer research, issued as paired R61 and R33 mechanisms under annual RFAs by NCI's Center for Strategic Scientific Initiatives. The FY25 cycle comprised four RFAs: RFA-CA-25-001 (R61 for molecular and cellular analysis technologies), RFA-CA-25-002 (R33 for advanced …

What this grant funds

Molecular and cellular analysis technologies; biospecimen science technologies for basic and clinical cancer research.

Key facts
CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Annual
Next deadlineiThe next date applications are due. Rolling means you can apply any time.—
Decision timeiTypical time from the deadline to the funder's decision.—
Project durationiHow long the funded work is expected to run.12–36 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.—
Funding analytics

Sign up free to see the funding breakdown

Create free accountSign in
Industries

Sign up free to see the industries in scope

Create free accountSign in
Eligibility criteria

Sign up free to see the full eligibility

Create free accountSign in
Application process

Sign up free to see how to apply

Create free accountSign in
What you have to submit

Sign up free to see what you submit

Create free accountSign in
Timeline

Sign up free to see the timeline

Create free accountSign in
Last verified: 22 Jul 2026Source: simpler.grants.gov